TD Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.81K Hold
212
﹤0.01% 500
2025
Q4
$10.8K Sell
212
-582
-73% -$29.8K ﹤0.01% 437
2025
Q3
$44.1K Buy
794
+1
+0.1% +$59 ﹤0.01% 233
2025
Q2
$54.7K Buy
793
+585
+281% +$39.8K 0.01% 210
2025
Q1
$14.5K Hold
208
﹤0.01% 285
2024
Q4
$17.9K Hold
208
﹤0.01% 251
2024
Q3
$24.8K Hold
208
﹤0.01% 237
2024
Q2
$29.6K Buy
208
+2
+1% +$265 ﹤0.01% 218
2024
Q1
$26.5K Hold
206
﹤0.01% 222
2023
Q4
$21.4K Hold
206
﹤0.01% 242
2023
Q3
$18.8K Hold
206
﹤0.01% 240
2023
Q2
$16.7K Buy
206
+2
+1% +$163 ﹤0.01% 249
2023
Q1
$16.3K Hold
204
﹤0.01% 243
2022
Q4
$13.9K Hold
204
﹤0.01% 230
2022
Q3
$10K Buy
+204
New +$10.9K ﹤0.01% 238
2022
Q1
Sell
-202
Closed -$11K 265
2021
Q4
$11K Hold
202
﹤0.01% 260
2021
Q3
$10K Hold
202
﹤0.01% 250
2021
Q2
$8K Buy
202
+2
+1% +$78 ﹤0.01% 256
2021
Q1
$7K Hold
200
﹤0.01% 240
2020
Q4
$7K Sell
200
-800
-80% -$27.7K ﹤0.01% 212
2020
Q3
$35K Hold
1,000
0.01% 134
2020
Q2
$33K Hold
1,000
0.01% 129
2020
Q1
$30K Buy
+1,000
New +$29.8K 0.01% 121

Other funds holding NVO

TD Capital Management's NVO Position: Q1 2026 in Review

TD Capital Management held its Novo Nordisk (NVO) position steady in Q1 2026 at 212 shares worth $7.81K. The position accounts for ﹤0.01% of the portfolio, ranked #500.

TD Capital Management first reported a position in NVO in Q1 2020 and has held it in 23 quarters since. The position peaked at $54.7K in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • TD Capital Management held 212 shares of Novo Nordisk worth $7.81K as of Q1 2026.
  • TD Capital Management left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up ﹤0.01% of TD Capital Management's portfolio in Q1 2026, its #500 holding.
  • TD Capital Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 23 quarters since.
  • TD Capital Management's Novo Nordisk position peaked at $54.7K in Q2 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on TD Capital Management's 13F filing for Q1 2026, filed 11 May 2026.